|
◯ Alpha Helix
2026-09-07
|
| The Alpha Helix Brief · week of 2026-09-07 |
| Quiet week. Nothing new cleared the bar. |
| // TL;DR |
| › Quiet week: nothing new cleared the bar for the corpus. | | › Still worth reading: Semaglutide 13.6–16.6% (NCT05564117); Retatrutide 28.3% (NCT05929066); Cagrilintide 22.7% (NCT05567796). |
|
| 0 new · 0 human · 0 preclinical · 0 regulatory · corpus 24 |
| // Still worth reading |
|
13.6–16.6%
weight reduction
FDA APPROVED Semaglutide · NCT05564117
Oral semaglutide 25 mg in adults with overweight or obesity (OASIS 4)
Human · randomized
|
|
28.3%
weight reduction
HUMAN RCT Retatrutide · NCT05929066
Retatrutide in adults with obesity (TRIUMPH-1)
Human · randomized · n=2,339 · 80 weeks
|
|
22.7%
mean weight reduction
HUMAN RCT Cagrilintide · NCT05567796
Cagrilintide-semaglutide in adults with overweight or obesity (REDEFINE 1)
Human · randomized
|
|
Open the Evidence Map
|
For research and laboratory use only. Not for human consumption.
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
Educational summary of published research. Not medical advice.
@alphahelix.health · What the evidence actually says.
Unsubscribe
|